pharmaceuticals firm based in India, Biophore India Pharmaceuticals has received a license from the Drug Controller General of India (DCGI) to manufacture Favipiravir.
The active pharmaceutical salt is an important part of the finished formulation to treat mild to moderate Covid-19 cases.Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.The drug has also received acceptance in Russia and parts of middle east in order to fight against Covid-19.
Other than these regions, it is also in advanced stage trials in other parts of the world.The new drug also received approval for exports as well.